Details

Autor(en) / Beteiligte

• Shah, Gaurav D.
• Loizos, Nick
• Youssoufian, Hagop
• Schwartz, Jonathan D.
• Rowinsky, Eric K.

Titel

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Ist Teil von

• Cancer, 2010-02, Vol.116 (S4), p.1018-1026

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2010

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• A large body of evidence suggests that the platelet‐derived growth factor (PDGF) family and associated receptors are potential targets in oncology therapeutic development because of their critical roles in the proliferation and survival of various cancers and in the regulation and growth of the tumor stroma and blood vessels. Several small molecules that nonspecifically target the PDGF signaling axis are in current use or development as anticancer therapies. However, for the majority of these agents, PDGF and its receptors are neither the primary targets nor the principal mediators of anticancer activity. IMC‐3G3, a fully human monoclonal antibody of the immunoglobulin G subclass 1, specifically binds to the human PDGF receptor α (PDGFRα) with high affinity and blocks PDGF ligand binding and PDGFRα activation. The results of preclinical studies and the frequent expression of PDGFRα in many types of cancer and in cancer‐associated stroma support a rationale for the clinical development of IMC‐3G3. Currently, IMC‐3G3 is being evaluated in early clinical development for patients with several types of solid malignancies. Cancer 2010;116(4 suppl):1018–26. © 2010 American Cancer Society. The platelet‐derived growth factor (PDGF)/PDGF receptor α (PDGFRα) signaling axis is a rational target for anticancer therapeutic development, because it plays a critical role in cancer growth, survival, and metastasis and in modulation of the stromal and angiogenic support for cancer growth. This article reviews the rationale for targeting the PDGF/PDGFRα signaling axis and focuses on IMC‐3G3, a fully human immunoglobulin G subclass 1 antibody that targets PDGFRα. IMC‐3G3 is undergoing early clinical development as an anticancer therapeutic.